Glucosamine and lower mortality and cancer incidence: Selection bias in the observational studies
暂无分享,去创建一个
[1] Dan Liu,et al. Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study , 2021, British Journal of Nutrition.
[2] L. Thabane,et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study , 2021, European Respiratory Journal.
[3] D. King,et al. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort , 2020, The Journal of the American Board of Family Medicine.
[4] S. Suissa,et al. Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis. , 2020, American journal of epidemiology.
[5] Raveendhara R. Bannuru,et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines , 2020, Nature Reviews Rheumatology.
[6] S. Suissa,et al. Time‐related biases in pharmacoepidemiology , 2020, Pharmacoepidemiology and drug safety.
[7] Xianbo Wu,et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study , 2020, Annals of the Rheumatic Diseases.
[8] L. Qi,et al. Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank , 2020, Diabetes Care.
[9] J. Reginster,et al. Glucosamine sulphate: an umbrella review of health outcomes , 2020, Therapeutic advances in musculoskeletal disease.
[10] Spiros C. Denaxas,et al. Avoidable flaws in observational analyses: an application to statins and cancer , 2019, Nature Medicine.
[11] L. Qi,et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank , 2019, British medical journal.
[12] S. Schneeweiss,et al. Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies , 2013, Pharmacoepidemiology.
[13] M. Egger,et al. Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations , 2018, BMC Medical Research Methodology.
[14] M. McCullough,et al. Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort , 2018, Cancer Causes & Control.
[15] C. Sudlow,et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population , 2017, American journal of epidemiology.
[16] M. Hernán. Invited Commentary: Selection Bias Without Colliders. , 2017, American journal of epidemiology.
[17] S. Suissa,et al. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism , 2017, Pharmacoepidemiology and drug safety.
[18] S. Suissa,et al. Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores , 2017, Pharmacoepidemiology and drug safety.
[19] E. Giovannucci,et al. Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow‐up study , 2016, International journal of cancer.
[20] Robert Platt,et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. , 2016, Journal of clinical epidemiology.
[21] J. Reginster,et al. Commentary on recent therapeutic guidelines for osteoarthritis. , 2015, Seminars in arthritis and rheumatism.
[22] S. Schneeweiss,et al. Practice of Epidemiology Implications of M Bias in Epidemiologic Studies: a Simulation Study , 2022 .
[23] A. Broom,et al. Who Uses Glucosamine and Why? A Study of 266,848 Australians Aged 45 Years and Older , 2012, PloS one.
[24] E. White,et al. Use of glucosamine and chondroitin in relation to mortality , 2012, European Journal of Epidemiology.
[25] M. Hernán,et al. Systematic Reviews and Meta-and Pooled Analyses Bias in Observational Studies of Prevalent Users : Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins , 2012 .
[26] S. Bae,et al. Prevalence and factors affecting glucosamine use in Korea: a survey-based study , 2013, Rheumatology International.
[27] E. White,et al. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort , 2011, Cancer Causes & Control.
[28] Johanna W Lampe,et al. Specialty Supplements and Prostate Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort , 2011, Nutrition and cancer.
[29] I. Scheel,et al. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. , 2010, JAMA.
[30] D. Reda,et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT , 2010, Annals of the rheumatic diseases.
[31] S. Cole,et al. Illustrating bias due to conditioning on a collider. , 2010, International journal of epidemiology.
[32] D. Reda,et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. , 2008, Arthritis and rheumatism.
[33] C. Berger,et al. Prevalence of and factors associated with glucosamine use in Canada. , 2006, Osteoarthritis and cartilage.
[34] M. Hernán,et al. The birth weight "paradox" uncovered? , 2006, American journal of epidemiology.
[35] Michael H Weisman,et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. , 2006, The New England journal of medicine.
[36] J. Robins,et al. A Structural Approach to Selection Bias , 2004, Epidemiology.
[37] S. Greenland. Quantifying Biases in Causal Models: Classical Confounding vs Collider-Stratification Bias , 2003, Epidemiology.
[38] T. Schnitzer,et al. Recommendations for the Medical Management of Osteoarthrits of the Hip and Knee , 2002 .
[39] George Davey Smith,et al. Meta-analysis: Principles and procedures , 1997, BMJ.
[40] O. Miettinen,et al. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. , 1989, Journal of clinical epidemiology.